Oklahoma viral hepatitis B and hepatitis C prevention and surveillance project - hepatitis B (HBV) and hepatitis C (HCV) are leading infectious disease causes of morbidity and mortality in oklahoma…

Oklahoma viral hepatitis B and hepatitis C prevention and surveillance project - hepatitis B (HBV) and hepatitis C (HCV) are leading infectious disease causes of morbidity and mortality in oklahoma (OK) and the united states. From 2014 to 2018, acute HBV cases kept around 40 to 57 cases annually reported to the OK state department of health (OSDH). The annual incidence rates of acute HBV in OK (range of 0.8 to 1.5/100,000 population during the recent 5-year period) are usually similar or higher than the rates in the US (0.9 to 1.1/100,000 population).with this notice of funding opportunity (nofo, the state of oklahoma intends to continue integrated viral hepatitis programs to: 1. Expand and improve both active and passive statewide surveillance for acute HBV and HCV; perinatal HCV; and chronic HBV and HCV. This provides a better picture of the disease burden of persons living with viral hepatitis infection in the state of OK and facilitates linkage to recommended care and treatment services. And to,2. Facilitate the development and implementation of viral hepatitis elimination plans in the state of OK by enhancing partnerships with healthcare, laboratories, and community-based organizations; and educating the providers, facilities, and laboratories on the potential or proven impacts of timely and complete reporting. Increase access to the prevention, diagnosis, and treatment of HBV and HCV, HIV, bacterial disease consequences of drug use among people who inject drugs (PWID) in settings disproportionately affected by drug use.oklahoma will follow the centers for disease control and prevention (CDC) project description for this nofo with measurable progress toward project period outcomes. Expected outcomes include improved surveillance for viral hepatitis, increased stakeholder engagement in viral hepatitis elimination planning, and improved access to viral hepatitis prevention, diagnosis, and treatment among populations most at risk.